NeuroMetrix Expands DPNCheck Commercialization in Mexico

NeuroMetrix Inc. today reported commercial expansion of DPNCheck in Mexico following receipt of a purchase order from one of Mexico’s six major government healthcare institutions. With this most recent order, two of these six major institutions have now adopted DPNCheck for early detection of diabetic peripheral neuropathy (DPN).
 
Mexico has one of the highest rates of diabetes in the world with a prevalence of nearly 10.8 percent as reported by The Organization for Economic Co-Operation and Development (OECD). The disease results in 80,000 deaths per year making diabetes the second leading cause of death for the country. The prevalence of diabetes is projected to increase in the coming years.
 
Scienta Farma, S.A.de C.V. is the exclusive distributor of DPNCheck in Mexico. The most significant market opportunity is within the public institutions that provide healthcare services to the majority of Mexico’s 120 million citizens. Scienta Farma focuses its marketing and sales efforts on government contracts with these institutions.
 
“DPNCheck is ideally suited for rapid screening of DPN in a large patient population,” said Alberto Elias Fernandez, executive vice president of Scienta Farma. “We believe that clinical adoption will advance the overall management of diabetes in Mexico.”
 
“Mexico is an increasingly significant component of our DPNCheck business,” said Michael MacDonald, NeuroMetrix senior vice president of Commercial Operations. “Scienta Farma is doing a great job in growing adoption within the critical governmental healthcare sector.”
 
DPNCheck is a quantitative nerve conduction test that is used by physicians and health care professionals to evaluate systemic neuropathies such as diabetic peripheral neuropathy, or DPN. It is designed to be used at the point-of-care to objectively detect, stage, and monitor DPN. The device measures nerve conduction velocity and response amplitude of the sural nerve, a nerve in the lower leg and ankle. These parameters are recognized as sensitive and specific biomarkers of DPN.
 
NeuroMetrix develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Mass., and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996.